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The composition and physical properties of the extracellular matrix (ECM) critically influence 
tumour cell behaviour, and ECM deposition and remodelling by stromal fibroblast populations 
is therefore pivotal for tumour progression. The molecular mechanisms by which stromal and 
tumour cell populations regulate ECM layering are poorly understood. Tumour-stroma 
interaction is critically dependent on cell-cell communication mediated by exosomes, small 
vesicles secreted by most cell types and generated within multivesicular bodies (MVBs). Here, 
we show that caveolin-1 (Cav1), an essential regulator of stromal remodelling and tumour cell 
fate, plays a central role in modulating both exosome biogenesis and exosomal protein cargo 
sorting through cholesterol-dependent mechanisms. Quantitative proteomics profiling 
revealed that a major share of Cav1-dependent exosomal cargoes are compsed of ECM 
proteins, one of the most important components being tenascin-C (TnC). Comparative 
functional assays demonstrated that Cav1 is required for fibroblast-derived exosomes to 
depose ECM and promote tumour cell invasiveness. Exosomes purified from Cav1WT cells, 
but not those from Cav1-null cells, were able to nucleate distant stromal niches in different 
organs in vivo. These findings suggest a key role for Cav1 as a cholesterol rheostat in MVBs, 
and seems to determine ECM deposition by eliciting ECM component sorting into specific 
exosome pools. These results, together with previous work, support a model in which Cav1 is 
a central regulatory hub for tumour-stroma interactions through a novel exosome-dependent 


















The tumour microenvironment is increasingly recognized as a key factor in multiple stages of 
disease progression, particularly local invasion and distant metastasis1-3. Cancer-associated 
fibroblasts (CAFs) are an important cell population in different carcinomas and constitute a 
major source of paracrine growth factors and ECM components for the tumour stroma 4,5. 
However, understanding is limited on the molecular mechanisms that determine fibroblast 
ECM deposition. Recent studies confirm that ECM deposition ultimately depends on a 
functional core secretion machinery6, but further mechanistic characterization of ECM 
deposition is needed to fully characterize the broad impact of the ECM in health and disease 
and explore new therapeutic opportunities.  
An important mechanism governing tumour-stroma interaction is exosomal cell-cell 
communication. Exosomes are secreted vesicles containing a variety of cargoes, and are 
generated from intraluminal vesicles (ILVs) in subpopulations of multivesicular bodies (MVBs), 
which are membrane-bound compartments intimately linked to the endosomal system7-9. 
Secreted by most cell types, exosomes enable a given cell to modulate the behaviour of other 
cell populations through the transfer of effector or regulatory molecules over long (inter-organ) 
distances10,11. Recent studies indicate that tumour-derived exosomes can promote pre-
metastatic niche formation12-14. However, it remains unclear whether and how fibroblast-
derived exosomes might modulate these phenomena during tumour progression. 
Exosomal cargo composition is heterogeneous and complex, containing a variety of 
proteins, small ligand peptides and regulatory nucleic acids9. It is clear that exosome 
composition, established by the donor cell, defines the modulatory effect on the receptor 
population, but little is known about how cargoes are selectively sorted into exosomes. Current 
evidence supports the co-existence of mechanisms dependent on the endosomal sorting 
complexes required for transport (ESCRT) machinery with ESCRT-independent 
mechanisms15,16, likely reflecting the heterogeneity of MVBs and exosomes and their potential 
differential impact on health and disease. 
Exosome biogenesis is also modulated by lipids through their ability to laterally 
segregate into specific membrane subdomains, which allows sorting platforms to be organized 
on the limiting membrane of MVBs 17. Cholesterol is likely to be a highly relevant lipid in this 
context, given its significantly higher abundance in MVBs than in other endomembrane 
compartments 18 . Cholesterol is necessary for the formation of high-curvature membrane 




membranes destined for exosome secretion has been also proposed19-21. However, 
information remains scarce on the mechanisms modulating cholesterol levels in MVBs and 
their impact on exosome biology. 
Contact sites between endosomes/MVBs and the ER membrane have recently been 
demonstrated as sites for the specific transfer of proteins and lipids (especially cholesterol). 
Modulation of ER-MVB contacts depends on the interaction between different proteins, 
especially members of the ORP family (ORP1L and ORP5). Cholesterol accumulation in 
MVBs has been reported to reduce ER-MVB contacts 22. 
Endomembrane trafficking is regulated by caveolin-1 (Cav1), an essential scaffolding 
component of invaginated plasmalemal nanodomains (caveolae). Cav1 participates in several 
essential cell functions, including sensing and transduction of mechanical cues, endocytosis, 
spatiotemporal control of signal transduction, and cholesterol homeostasis. Moreover, we 
recently identified Cav1 as an integral component of mitochondria-associated ER membranes 
(MAMs), which are specialized ER regions that allow communication with mitochondria 23. The 
pleiotropic functions of Cav1 support a pervasive yet context-dependent role in cancer 
progression and metastasis 24. These diverse Cav1 functions include biomechanical 25 and 
compositional 26 remodelling of the ECM by CAFs to favour tumour invasion and metastasis, 
but the mechanisms through which Cav1 regulates ECM composition are unknown. Cav1 has 
been detected in exosomes27, but it has not been determined whether exosomal secretion is 
a specific means for Cav1-dependent ECM remodelling. 
Here we demonstrate that Cav1 is a constitutive component of exosomes produced by 
several cell types, including primary CAFs. We show that ubiquitination-acceptor lysines at 
the N-terminal region of Cav1 are essential for its sorting into the MVB compartment. 
Comparative proteomic and lipidomic studies showed that Cav1 modulates the sorting of 
exosome cargo and the segregation of exosome subpopulations through a cholesterol-
dependent mechanism. Intriguingly, exosomes derived from Cav1WT fibroblasts are 
significantly enriched in ECM components, including TnC, an important driver of tumour 
progression. Complementary in vitro approaches indicate that exosomal biogenesis and 
release are essential for fibroblast ECM deposition. Supporting Cav1-dependence of exosome 
competency for ECM deposition, exosomes derived from Cav1-null fibroblasts failed to 
promote protrusiveness, motility and invasiveness in a breast tumour cell line. Cav1-
dependent remote ECM deposition by exosomes was recapitulated in vivo, suggesting an 
important role for stromal Cav1 in distant premetastatic niche formation in addition to its 
reported role in local ECM remodelling. We propose that Cav1 is a key regulatory hub 




exosome biogenesis and specific exosomal cargo sorting. This regulation is exerted through 








Internalized Cav1 redistributes to LE/MVB to its sorting in exosomes 
 
Caveolin-1 internalization is tightly regulated28-30. Although endocytosed Cav1 has commonly 
been regarded as committed to degradation31,32, alternative fates cannot be excluded33. To 
better define this process, we conducted confocal microscopy analysis of endogenous Cav1 
trafficking dynamics in mouse embryonic fibroblasts (MEFs) and COS7 cells upon treatment 
with sodium orthovanadate, which induces Cav1 internalization by protecting Cav1 
phosphorylation at tyrosine 1430. Orthovanadate exposure induced Cav1 phosphorylation, 
which correlated with increased colocalization with the late endosome (LE; immunostained 
with a monoclonal antibody to lyso-bis-phosphatidic acid (LBPA)) and multivesicular bodies 
(MVBs; immunodecorated for the CD63 marker) (Fig. 1a and Supplementary Fig.1a). 
Similarly, a significant fraction of Cav1 relocalized to the LE/MVB compartment upon exposure 
of cells to EDTA, which induces Cav1 endocytosis by promoting cell detachment 34, and in 
response to RNAi-mediated depletion of PTRF, an essencial caveolar coat component 
required for caveolae stabilization35 (Supplementary Fig. 1b and 1c). Interestingly, PTRF 
depletion induced significant Cav1 phosphorylation (Supplementary Fig. 1c). High-resolution 
confocal microscopy confirmed the constitutive presence of Cav1 in the MVB lumen, 
colocalizing with the exosomal marker CD63 in normal conditions (Fig. 1b). To confirm Cav1 
internalization in LE and MVB lumens, we generated enlarged endosomes by overexpressing 
a constitutively active Rab5 mutant (Q79L)36. Discrete patches of Cav1 clearly localized to 
ILVs within MVBs (Fig. 1c), delineated by accumulation of the specific exosomal markers 
Tsg101 and CD63 (Supplementary Fig. 1d). These observations demonstrate that MVBs are 
one of the destinies of endocytosed Cav1. 
Phosphorylation and ubiquitination engage in an intricate interplay, with phosphorylation often 
serving as a trigger for subsequent ubiquitination of adjacent acceptor residues37. 
Ubiquitination and deubiquitination appear to be important steps for protein sorting into ILVs 
within MVBs. To assess the importance of ubiquitination for Cav1 internalization into MVBs, 
we analyzed the subcellular distribution of Cav1 mutants in which arginine residues replace 
lysine residues that act as ubiquitination acceptors (Fig. 1d, upper panel). All mutant forms 
nicely decorated the outer enlarged-Rab5 endosome membrane/MVB; however, mutation of 
the N-terminal lysine cluster (K5-57R and K5-176R mutants) abolished Cav1 sorting into ILVs 




38. This result correlated with lower overall colocalization of these mutants with CD63 
(Supplementary Fig. 1e). In contrast, mutation of lysine residues in the carboxyl-terminal Cav1 
region (K65-176R mutant) did not affect the ability of Cav1 proteins to localize in MVBs (Fig. 
1d). Interestingly, the overall phosphorylation level in these Cav1 mutants was not significantly 
altered (Fig. 1e), reinforcing the notion of a two-step mechanism driving Cav1 sorting into 
MVBs, with phosphorylation first eliciting Cav1 internalization towards the outer MVB 
membrane and ubiquitination then acting as a check-point for proper Cav1 sorting into the 
ILVs. 
To test whether the ILV-localized Cav1 pool is effectively sorted into exosomes, we analyzed 
density gradient-purified exosomes from different cell lines (including tumour and fibroblast 
cells) by western blotting. Endogenous Cav1 mainly partitioned with Tsg101, confirming that 
exosomes can carry Cav1 (Fig. 1f). Interestingly, Cav1 sorting to exosomes was favoured in 
PTRF-depleted MEFs (Supplmentary Figure 1f), opposite to the impaired sorting of Cav1 
mutants with disrupted N-terminal ubiquitination (Fig 1g). Taken together, these data strongly 
suggest that a significant proportion of internalized Cav1 sorts to the MBV lumen in an 
ubiquitin-dependent manner, favouring its incorporation into exosomes. Furthermore, 
internalization of endogenous Cav1 into exosomes is a constitutive process in all Cav1-
expressing cell lines tested.  
 
Cav1 regulates exosomal biogenesis through modulation of MVB cholesterol content 
A variety of mechanisms can modulate the composition and organization of membranes 
incorporated into MVBs, resulting in different ILV and exosome populations9. Because Cav1 
is a key organizer of membrane architecture across cell compartments24, we explored whether 
Cav1 plays an active role in exosome biogenesis. Genetic ablation of Cav1 did not trigger a 
general, non-specific alteration of exosomal biogenesis; indeed, Cav1KO fibroblasts had even 
higher rates of exosome secretion, as determined by western blot of total purified exosomes 
from equal cell numbers (Fig. 2a upper panel and Figure 2b), sedimentation across sucrose 
density gradients (Fig. 2a lower panel), and physical characterization with Nanosight 
technology and transmission electron microscopy (TEM) (Fig. 2c and Fig. 2d)39. However, 
Nanosight and TEM identified two differently sized exosome subpopulations in Cav1WT 
fibroblasts, whereas Cav1KO fibroblasts produced a homogeneous population containing the 





The ability of Cav1 to associate with specific lipids, particularly cholesterol, and to generate 
specialized membrane organization domains 24,40prompted us to study whether Cav1 
promotes the exosome heterogeneity observed in preparations purified from Cav1WT MEFs 
by modulating cholesterol levels and membrane organization in MVBs. To explore this, 
Cav1WT and Cav1KO MEF cells were labelled with filipin, a well-known cholesterol marker. 
While the number of LBPA-positive structures did not differ between Cav1WT and Cav1KO 
fibroblasts, MVB area and filipin intensity (a proxy for mean cholesterol content) were 
significantly higher in Cav1KO cells (Figure 2e). This phenotype was recapitulated by siRNA 
depletion of Cav1 in Cav1WT cells (Supplementary Fig. 2a). Interestingly, treatment of 
Cav1WT MEFs with U1866A, a specific promotor of cholesterol accumulation in the LE/MVB 
compartment41, increased exosome secretion while reducing exosome heterogeneity, thus 
mimmicking the phenotype of Cav1KO cells (Fig. 2f). 
A major share of MVB cholesterol is contained in ILVs18. We confirmed this cholesterol 
accumulation in enlarged endosomes by overexpressing constitutively active Rab5Q79L 
(Supplementary Figure 2b). To confirm whether altered cholesterol content in Cav1KO MVBs 
induces changes in exosome membrane organization in these cells, we isolated cold-
detergent-resistant microdomains (exosome DRMs) from the exosomes produced by Cav1WT 
cells (control or U18666A-treated) and Cav1KO cells. Flotillin-1, a well-known marker of 
exosomes and liquid ordered domains, showed a wider distribution in Cav1KO cells (fractions 
1 to 8) or U18666A-treated Cav1WT cells (fractions 1 to 6); in contrast, flotillin accumulation 
in control Cav1WT-derived exosomes was restricted to fractions 1 to 3 (Fig. 2g), reflecting the 
increased high-ordered membrane content of Cav1KO-derived exosomes. Altered lipid 
composition as a major direct consequence of Cav1 deficiency in exosomes was further 
supported by mass spectrometry analysis of phosphatidic acid (PA), phosphatidylinositol (PI), 
and LBPA, which is essential for ILV budding from the MVB inner leaflet 42,43. Cav1WT-derived 
exosomes had significantly higher amounts than Cav1KO exosomes of these components 
(Supplementary fig. 2c). 
These results strongly indicate that Cav1 plays a key role in the modulation of exosome 
biogenesis by acting as a “cholesterol rheostat” in MVBs, thus conferring plasticity to this 
compartment and enabling the segregation of different exosome populations. 
 
Cav1 promotes the sorting of specific ECM cargoes into exosomes 
To determine whether Cav1-dependent heterogeneity in exosome size influences protein 




corresponding exosome preparations by isobaric labelling-based quantitative proteomics. This 
analysis identified a subproteome that is equally abundant in Cav1WT and Cav1KO whole-
cell lysates but whose components are differentially sorted to exosomes depending on Cav1 
genotype (Fig. 3a left panel). At a change threshold of |Zq| > 1.5, 152 proteins from this 
subproteome were more abundant and 163 proteins were less abundant in Cav1KO 
exosomes than in Cav1WT exosomes. Interaction network and functional annotation 
enrichment analysis revealed that Cav1WT-derived exosomes were significantly enriched in 
ECM components (including TnC, fibronectin, nidogen, emilin, EDIL3 and heparan sulfate 
proteoglycans) and endosomal/endomembrane system components (Fig. 3a right upper 
network, Fig3b, Supplementary Fig. 2d and Supplementary Table 1). Conversely, STRING 
network analysis revealed marked enrichment of Cav1KO exosomes for DNA/RNA binding 
and chaperone proteins such as histones (Fig. 3a right lower network, Fig 3b, Supplementary 
Fig. 2d and Supplementary Table 1). Consistent with our data supporting an increased 
cholesterol content in Cav1KO MVBs, various annexin family members were substantially 
enriched in Cav1KO exosomes, despite the slightly decreased abundance of these proteins 
in Cav1KO whole-cell lysates (Fig. 3c). Annexins are Ca2+-dependent proteins that bind 
cholesterol-rich membranes, providing lipid-clustering activity. Annexin enrichment in Cav1KO 
exosomes could may be a mechanism to sequester excess cholesterol in these exosomes.  
The differential exosome sorting of selected gene products was validated by conventional 
western blot analysis (Fig. 3d). A particularly marked difference was observed for TnC 
(Zq=3.02), an extracellular matrix protein involved in development, stem cell niche formation, 
and aggressive tumour metastasis44-46. TnC was prominently represented in Cav1WT-derived 
exosomes but virtually absent from Cav1KO exosomes (Supplementary Table 1). Consistent 
with these observations, TnC colocalized with Cav1 within MVBs in fibroblasts and U251 cells 
(a TnC-secreting glioblastoma cell line47) (Supplementary Fig. 2e). These results strongly 
support the view that Cav1 modulates exosome biogenesis and the sorting into exosomes of 
specific cargo proteins, especially ECM components. The data also suggest that Cav1 is a 
prominent regulator of exosome-mediated intercellular communication, with as-yet 
uncharacterized downstream biological functions. 
 
Exosome biogenesis/secretion modulates ECM deposition 
We next examined whether exosome-delivered ECM components can initiate de novo ECM 
deposition. Fluorescent immunolabelling and confocal microscopy revealed that Cav1KO 
fibroblast cultures deposit significantly less TnC fibre matrix in extracellular spaces than wild 




(Cav1KD) (Fig. 4a). TnC fibre deposition was also reduced by treatment of Cav1WT cells with 
the cholesterol trafficiking inhibitor U18666A (Fig. 4b and 4c and Supplementary Fig. 3b). 
Reduced TnC deposition associated with Cav1 downregulation or genetic deletion was 
concomittant with intracelular TnC accumulation; in contrast, U18666A-treated wild-type cells 
showed less evident intracellular TnC retention, probably reflecting a much higher rate of TnC 
degradation in this condition (Fig. 4b). Importantly, TnC was significantly less abundant in 
exosomes derived from Cav1KO and Cav1KD MEFs or U18666A-treated Cav1WT MEFs (Fig. 
4d and Supplementary Fig. 2f), supporting a link between exosomes and TnC matrix 
deposition. To assess the contribution of exosomes to extracellular TnC fibre deposition, we 
treated Cav1WT fibroblasts with one of two available exosome secretion inhibitors: 
dimethylamiloride (dMA), an H+/Na+ and Na+/Ca2+ channel inhibitor, and GW4869, a neutral 
sphingomyelinase-2 (nSMAse2) inhibitor36,48. Net exosome release by Cav1WT fibroblasts 
was reduced by nSMAse2 blockade, and to a lesser extent by H+/Na+ and Na+/Ca2+ channel 
blockade (Supplementary Fig. 3a), correlating with an impaired ability to deposit extracellular 
TnC fibres (Fig. 4e). Both treatments also provoked the accumulation of dense intracellular 
TnC aggregates (Supplementary Fig. 3c). Importantly, the deposition of fibronectin (FN), 
another key ECM component underrepresented in Cav1KO exosomes (Fig. 3b and 
Supplementary table 1), was also reduced by exposure to exosome secretion inhibitors, with 
GW4869 having a much stronger effect (Fig. 4f). The general impact of exosome secretion on 
ECM deposition was also confirmed in primary cancer-associated fibroblasts (CAFs), a tumour 
stroma population with a key role in cancer progression. Exosome release by CAFs was 
largely inhibited by GW4869, whereas dmA had virtually no effect (Supplementary Fig. 4a). 
Accordingly, TnC and FN deposition by CAFs was specifically affected by nSMAse2 blockade, 
whereas dMA had no effect (Supplementary Fig. 4b and 4c). Confocal analysis and 
quantitative ER stress assays showed that neither GW4869 nor dMA affected the function or 
structure of ER-Golgi compartments in MEFs or CAFs (Supplementary Fig. 3d and 3e and 
Supplementary Fig. 4d and 4e), ruling out compromised ER-Golgi secretory function as a 
possible cause of the defective deposition of ECM components.  
Because ESCRT machinery-regulated trafficking and ceramide biogenesis pathways are 
thought to generate exosomes with different cargoes9, we analyzed the effect on TnC matrix 
deposition of transient knockdown of Tsg101 (a core regulator of the ESCRT-dependent 
pathway) or of nSMAse1 and 2 (key regulators of ceramide metabolism) (Supplementary Fig. 
3f and 3g). Consistent with the results obtained with small compound inhibitors (Fig.4e), 
knockdown of either pathway impaired TnC deposition; however, the phenotype was stronger 
upon ceramide synthesis disruption (Fig. 4g and Supplementary Fig. 3h). Similarly, the same 




These data support a role of exosomes as a general ECM deposition mechanism, with 
ceramide-dependent exosome biogenesis as a major limiting step in this process. 
 
TnC pools incorporated into exosomes have an intracellular origin 
We next investigated the mechanisms underlying TnC incorporation into exosomes. To rule 
out an external orgin of exosome-incorporated TnC through endocytic trafficking, we 
developed an assay based on cell-derived matrices (CDMs). CDMs were generated by 
decellularization of ECMs synthesized in vitro by TnCWT or TnCKO MEFs. Immunostaining 
and microscopy analysis confirmed that TnCKO cells were specifically impaired for TnC 
deposition but not for deposition of other ECM components such as FN (Fig. 5a and 
Supplementary Fig. 4f). TnCKO or TnCWT cells were then seeded on each of these CDMs 
(Fig. 5b) and TnC internalization was determined by western blot. No intracellular TnC was 
detected inside TnCKO fibroblasts grown on TnC-rich CDMs, thus excluding endocytosis as 
an active TnC pool for exosome cargo sorting. 
This finding left open the possibility that TnC detected in purified exosome fractions might 
originate in the passive, nonspecific binding of extant extracellular TnC fibres to the surface of 
secreted exosomes. To exclude this, purified exosomes from TnCKO cells were incubated 
with TnC-rich matrix produced by TnCWT cells (see scheme in Fig. 5c). After a second round 
of exosome purification, western blot analysis failed to detect TnC protein in TnCKO exosomes 
even after their incubation with TnC-rich matrix (Fig. 5c).  
To further characterize TnC supply to exosomes, we conducted sucrose gradient 
ultracentrifugation analysis to separate MVBs from the endoplasmic reticulum (ER) and Golgi 
compartments (which fractionate together). In untreated Cav1WT cells, TnC co-sedimented 
with the MVB marker CD63 and the ER marker calreticulin (Fig. 5d); however, upon treatment 
with the exosome release inhibitor GW4869, TnC was largely excluded from CD63-positive 
fractions, a distribution shift recapitulated in Cav1KO-derived cell homogenates (Fig. 5d). 
Moreover, immunofluorescence analysis again revealed a major fraction of cellular TnC 
colocalizing with the ER marker in Cav1KO cells or GW4869-treated Cav1WT cells (Fig. 5e 
and Supplementary Figure 4g). Interestingly, this colocalization was significantly enhaced in 
the presence of the lysosomal inhibitor chloroquine. These results suggest that defective 
transfer of TnC from the ER to MVBs results in retention of TnC in the ER and its subsequent 
targeting for degradation, supporting the idea that lysosomal degradation is a mechanism of 
TnC removal when its sorting into exosomes is impaired. Degradation rate differences could 




treated with exosome inhibitor drugs and why severe disruption of exosome biogenesis and 
secretion does not entail a robust engagement of the unfolded protein response. 
Together, these observations strongly support the view that the presence of TnC in exosomes 
reflects true regulated intracellular sorting of TnC into MVBs, likely through a mechanism 
involving ER-MVB contact sites, and that this exosomal TnC pool is sourced in the cell from 
de novo translation and not from endocytosed material. 
Cav1-dependent exosome biogenesis directy drives ECM deposition and subsequent 
increase in tumour-cell invasiveness. 
We next compared the ability of purified exosomes derived from either Cav1WT or Cav1KO 
MEFs to deposit TnC on 2D cultures of the non-invasive breast cancer tumour cell line MDA-
MB468, which naturally expresses negligible levels of Cav1 and TnC49. After 24h, tumour cells 
internalized pre-labelled Cav1WT and Cav1KO exosomes with similar efficiency, as shown by 
similar accumulation of the general membrane dye PKH67 (Fig. 6a, in green). However, only 
Cav1WT-derived exosomes led to detectable deposition of TnC in areas close to the periphery 
(Fig. 6a, in red). In contrast, MDA-MB468 cultures exposed to Cav1KO exosomes showed 
baseline levels of TnC deposition comparable to those displayed by control cultures (exposed 
to vehicle). Exosomes thus have an intrinsic ability to deposit specific ECM material in vitro 
that requires Cav1-dependent regulation of exosome biogenesis, likely derived from the 
specification of cargo profile. 
The deposition of TnC delivered by Cav1WT-derived exosomes induced important 
morphological changes in receptor MDA-MB468 tumour cells, eliciting cell-cell adhesion loss 
and internalization of the epithelial marker E-cadherin, associated with increased 
protrusiveness and emission of filopodia (Fig. 6b). A similar phenotype was produced by using 
CAF lines transduced with lentiviral vector encoding Cav1 shRNA (Supplmentary Figure. 5b). 
Consistent with these EMT-like changes, MDA-MB468 cells concomitantly acquired an 
increased ability to migrate, as determined in wound healing studies and transwell cell 
migration assays (Supplementary Fig. 5c and 5d). In contrast, exposure of MDA-MB468 cells 
to purified exosomes derived from Cav1KO fibroblasts induced no significant morphological 
changes (Fig. 6a and 6b). Interestingly, exosomes purified from MDA-MB231 tumour cells, 
which contain Cav1 but not TnC, also failed to induce an increase in MDA-MB468-cell 
protrusiveness and motility (Supplementary Fig. 5a and Supplementary Table 2), strongly 





The in vivo setting is more closely modelled by 3D culture methodologies50. We thus studied 
the ability of exosomes to deposit ECM on MDA-MB468 spheroids. Spheroids are scaffold-
free 3D assemblies in which cells self-organize ECM and engage in intercellular 
communication; spheroids have been validated as superior in vitro experimental proxies of 
live tissues for many applications50,51 . Consistent with the 2D culture experiments, Cav1WT-
derived TnC-containing exosomes, but not exosomes derived from Cav1KO or Cav1KD 
fibroblasts (i.e. TnC-depleted), efficiently deposited fibrillar TnC structures within cell 
spheroids (Fig. 6c). 3D-reconstruction of confocal optical sections across the whole spheroid 
volume demonstrated that TnC fibrils were preferentially located in the interstitial space, 
enveloped by the peripheral actin of the cell membranes (Supplementary Fig. 5e). These 
experiments further support the view that exosomes from Cav1WT MEFs carry ECM 
components and are able to transfer these components to tumour cells for the deposition of 
new ECM. 
To characterize Cav1-dependent, exosome-induced phenotypic changes in tumour cells, we 
monitored the boundary of MDA-MB468 spheroids over 72 h. Spheroids generated in the 
presence of Cav1WT-derived exosomes were seeded onto a plate and cells were allowed to 
migrate away from the spheroid. Cav1WT MEF-derived exosomes promoted significantly 
more migration than exosomes derived from Cav1KO MEFs (Fig. 6d). To confirm the role of 
TnC in this process, we tested the effect of exosomes derived from TnCKO MEFs 
(Supplementary Fig. 5f and 5g). TnCKO exosomes were poor stimulators of cell migration, 
supporting the view that the ability of Cav1WT MEF-derived exosomes to induce phenotypic 
changes in target tumour cells derives largely from Cav1-dependent sorting of specific ECM 
cargoes to exosomes. 
We next examined whether exosome-induced tumour-cell protrusiveness and migration was 
associated with increased invasiveness through different substrates. Compared with 
exosomes derived from other sources, Cav1KO exosomes consistently exhibited a blunted 
ability to induce invasiveness in Matrigel invasion assays (Fig. 6e) or 3D collagen matrix 
invasion assays (Fig. 6f), similar to the reduced invasion promoted by exosomes derived from 
TnCKO cells (Fig. 6g)). These results further support the relevance of Cav1- and TnC-
dependent exosome-induced ECM deposition and phenotype alteration for tumour 
progression. 
Cav1WT MEF-derived exosomes create TnC-rich niches in vivo 
We next evaluated whether exosomes deposit TnC in vivo, surviving vascular dissemination 
over large (inter-organ) distances. We fluorescently labelled the membranes of exosomes 




mice every day for 1 week (Fig. 7a). Histopathological analysis revealed specific exosome 
accumulation in liver, and to a lesser extent, in lung (Fig. 7b and Supplementary Fig. 5h). 
However, associated TnC deposition was only consistently detectable in liver and lung of mice 
injected with Cav1WT-derived exosomes, contrasting the residual TnC staining in the organs 
of animals injected with Cav1KO exosomes or vehicle (PBS), despite Cav1KO derived-
exosomes being able to reach to this organ with comparable efficiency. Intriguingly, TnC from 
Cav1WT exosomes tended to accumulate preferentially in liver sinusoids (Fig. 7b), whereas 
in the lung TnC deposition was concentrated in areas surrounding mesenchymal cells 
(Supplementary Fig. 5h). Moreover, Cav1WT-derived exosomes showed a moderate 
preference to accumulate in liver rather than lungs, whereas Cav1KO exosomes showed no 
such preference, despite efficient uptake across organs. These organ-specific peculiarities 
might indicate a Cav1-dependent role for exosomes in targeting a specific cell subpopulation 
for niche formation. 
Our observations thus support a key role for Cav1 in exosome-dependent ECM deposition in 
vivo. TnC is a positive regulator of metastasis through the assembly of favourable distant 
microenvironments52, suggesting that Cav1 might specifically modulate cancer outcome 
through exosome-dependent stroma-tumour communication. 
 
DISCUSSION 
Exosomes have recently attracted attention due to their potential to provide a means by which 
tumour cells and associated stroma not only communicate locally, but also influence and 
transform distant locations or ‘niches’ and even modulate organismal responses 
systemically12-14 . Despite the ubiquity of exosomes, the mechanisms underlying exosome 
biogenesis, cargo sorting, and function remain elusive. Here, we demonstrate the role of Cav1 
as a modulator of exosome biogenesis through the regulation of cholesterol content in MVBs. 
Cav1-dependent cholesterol modulation in this compartment permits the generation of 
exosomes with a higher heterogeneity, specifying exosome cargo subsets (mainly specific 
ECM proteins) and subsequent functional impacts. Our data demonstrate that the presence 
of Cav1 within exosomes is favoured by its endocytosis through specific phosphorylation at 
tyrosine 14. This phosphorylation step promotes Cav1 targeting to the MVB outer membrane, 
where a second mechanism is activated that requires the presence of ubiquitination-targeting 
N-terminal domain lysine residues; this second mechanism sorts Cav1 into ILVs for exosome 
generation. By virtue of its cholesterol-binding ability, Cav1 would act as a “cholesterol 




segregation of different exosome populations, a phenomenon that as we have demonstrated 
can be perturbed by pharmacological treatments that directly affect intracellular cholesterol 
trafficking. The importance of cholesterol regulation in this compartment could also determine 
how exosome protein cargo is specified through modulation of contact between the ER and 
MVBs. (Fig. 7c, enlarged graph). 
Among the exosome-targeted ECM proteins identified, TnC is a key component involved in 
promoting exosome-dependent tumour invasion. TnC matrix deposition mediated by Cav1-
expressing fibroblasts requires intact exosome biogenesis and secretion, as demonstrated by 
the effect of exosome inhibitors and siRNAs targeting exosome biogenesis-machinery 
components. Furthermore, our data support a model whereby the ER/Golgi compartment is a 
major direct supplier of TnC to these exosomes. 
Exosomes secreted by Cav1WT fibroblasts have a dual effect, on the one hand stimulating 
protrusiveness and active migration of targeted tumour cells by inducing an EMT-like process, 
and on the other hand eliciting ECM deposition in areas surrounding the tumour. We 
demonstrate that this effect also takes place in vivo over large distances, suggesting that these 
mechanisms contribute to tumour-cell invasiveness and favour the establishment of distant 
metastatic foci by nucleating new ECM deposition (Fig. 7c).  
Cav1 is trafficked through several endomembrane systems, including late endosome/MVBs 
and lysosomes, suggesting the likely existence of several as yet unidentified caveolae-
independent Cav1 functions 24,53. Previous studies demonstrated that caveolae budding from 
the plasma membrane carry Cav1 to early endosomes, presumably allowing dynamic 
recycling and maintenance of these structures54. However, an alternative pathway has been 
described in which caveolae are disassembled and Cav1 is internalized and ubiquitinated, 
followed by accumulation at the internal membrane of late endosomes/MVBs32,35 . 
Interestingly, Cav1 is also targeted to late endosomes by perturbations of lysosomal pH and 
changes in cholesterol content, with no changes in Cav1 degradation rate, raising the 
possibility of alternative fates for this Cav1 pool 33. Our data demonstrate that a significant 
pool of endocytosed Cav1 is sorted into MVBs en route to exosomes (Fig. 1), but we cannot 
rule out that other intracellular compartments such as the ER may also serve as a source of 
exosomal Cav1 (Fig. 1 and supplementary Fig. 1).  
Cav1 binds cholesterol with high affinity 40 and its ability to move between different 
compartments might contribute to the regulation of cholesterol fluxes and distribution within 
cells55. Our data demonstrate that Cav1 absence increases the level of free cholesterol in late 
endosomes/MVBs, suggesting that Cav1 is important for the modulation of membrane 




favour a specific and significant enrichment of extracellular matrix components in exosomes. 
(Fig. 2 and Supplementary Fig. 2 and Fig.3). Interestingly, among the identified Cav1-
dependent exosomal cargoes, collagens are less abundant than other matrix proteins such as 
TnC, fibronectin, laminin, nidogen, and emilin. Collagen secretion requires specific assembly 
mechanisms operating through the COPII biosynthetic/secretory machinery56, and is thus 
unavailable to the exosome pathway. (Fig3, Fig. 4 and Supplementary Fig. 3).These pathways 
might be oppositely regulated by Cav1, since a negative correlation has been described 
between Cav1 expression and collagen deposition in chronologically-aged skin and during 
fibrosis57,58 .Our results strongly suggest that a previously overlooked critical function of Cav1 
is ECM secretion via exosomes. Supporting our observation that exosomes can act as carriers 
of some extracellular matrix proteins, a recent study demonstrated exosomal secretion of FN 
through its binding to integrin α5β1; however, the function and underlying mechanism of this 
sorting were not determined.59,60  
In constrast to Cav1WT-derived exosomes, the homogeneous exosome population produced 
by Cav1null cells has a strong tendency to aggregate (data not shown), which could be directly 
linked to the ability of annexins, significantly enriched in Cav1null exosomes, to favour 
cholerestol-enriched membrane aggregation61. Intriguingly, in the absence of Cav1, the main 
exosome protein components are related to DNA/RNA binding and nuclear functions, cargoes 
that may be favoured in conditions of metabolic stress (Fig. 3b). 
Our data demonstrate the importance of TnC secretion via exosomes and point to 
incorporation of TnC into ILVs through its sorting from the biosynthetic route to the MVB 
compartment, excluding the possibility of an extracellular origin through its internalization into 
the cell or by direct binding to exosomes once they are released (Figure 5).  
Recent work has revealed the presence of contact sites between MVBs and the ER62,63, but 
the frequency, dynamics and physical architecture of these contacts are poorly understood. 
Interestingly, our group has demonstrated the importance of Cav1 as a main component of a 
section of the smooth ER that forms close contacts with mitochondria23, suggesting that Cav1 
may also modify ER-MVB contacts sites, thus modulating the incorporation of specific protein 
cargo into MVBs en route to exosomes.  
The similar effects of TnCKO and Cav1KO exosomes (Fig. 6) suggest that the biological 
actions determined by secretion of Cav1WT-derived exosomes directly depend on exosome 
TnC content. Our results suggest that TnC has a dual effect of on tumour progression. Over 
short distances, fibroblast-derived TnC-rich exosomes are deposited in areas surrounding 
tumour cells. The presence of TnC at the tumour invasive front presumably induces an EMT-




in 2D and 3D assays (Fig. 6). Similar results were obtained by direct addition of recombinant 
soluble TnC64. Together with this local effect, our data provide evidence for exosome-mediated 
TnC deposition over large distances to sites in lung and liver. Recent findings demonstrate 
that the microenvironment required for the formation of secondary metastatic sites is primed 
before the arrival of cancer cells, forming a “landing dock” for future metastatic growth65. 
Establishment of a pre-metastatic niche is a multistep process involving the sequential 
activation of several cell types, as recently shown for metastasis of pancreatic cancer to liver13. 
We propose that this orchestrated cascade is complemented by alternative mechanisms that 
directly promote pre-metastatic niche formation. Our results show that caudal vein injection of 
exosomes derived from Cav1WT fibroblasts can promote direct TnC-matrix deposition in 
distant organs (Fig. 7). 
In addition to the role of exosomes in tumour progression, altered extracellular vesicle 
secretion is also linked to several cholesterol-related diseases 66,67. This attracts particular 
attention in relation to atherosclerosis, where exosomes may be involved in monocyte and 
macrophage cholesterol metabolism, endothelial cell and platelet activation, and smooth 
muscle proliferation. Interestingly, Cav1 loss results in hypercholesterolemia but also protects 
against the development of aortic atheromas. Further investigation will be required to confirm 
whether modulation of exosomal Cav1 incorporation might provide an alternative way to 
modulate cholesterol levels as well as thre specific proatherogenic molecule cargo. The 
lysosomal storage disorder Niemann-Pick Type C (NPC) disease is also characterized by 
cholesterol accumulation in the endosomal-lysosomal system 68. Whether exosomes can 
serve as diagnostic and therapeutic tools for NPC patients remains to be determined. Although 
the specific connections between cholesterol homeostasis and exosomes remain unclear, 
Cav1 appears to be a key player in this interaction. 
Previous studies demonstrated high levels of Cav1-expressing exosomes in the plasma of 
melanoma patients 27. We propose that relative levels of Cav1-expressing exosomes could be 
a valuable prognostic marker of metastasis and tumour malignancy as well as another 
cholesterol-related diseases. Our findings suggest new avenues for diagnosis, prevention, 
and therapeutic intervention based on specifically targeting Cav1-dependent roles in 













Figure 1. Internalized Cav1 is sorted to exosomes      
(a) Confocal microscopy of caveolin-1 (red) and LBPA (green) in Cav1WT MEFs after 
treatment with sodium orthovanadate for 2 h. White arrows indicate plasma membrane Cav1 
localization and grey arrows mark Cav1 relocalization to the perinuclear area (Scale bar, 25 
µm). Charts show quantification of Cav1-LBPA colocalization. Error bars represent mean±s.d; 
n=80 cells. Representative western blot of phospho-Cav1 and total Cav1 in sodium 
orthovanadate-treated cells. (b) Colocalization between Cav1 and the MVB/exosome marker 
CD63. The right panels show high-resolution views of an MVB compartment after image 
deconvolution (Scale bar, 1 µm). (c) Cav1 distribution in Rab5(Q79L)-COS7-expressing cells 
(Scale bar, 10 µm). A zoomed view of an endosome is shown on the right (Scale bar, 2,5µm). 
(d) Top. Ubiquitination-target lysine residues (Ub) in WT Cav1 and engineered versions with 
the indicated residues mutated to arginine (X). Bottom. Confocal analysis of COS7 cells 
transfected with Rab5(Q79L) (green) and the indicated Cav1 proteins. Ubiquitination is lost 
upon mutation of the N-terminal region lysines (K5-57R) or all lysines (K5-176R), but not 
lysines 65-176 (K65-176R) (as reported in Kirchner et al., 2012) (Scale bar, 10 µm). The chart 
compares localization of Cav1 variants in the endosomal lumen (internal, INT: white) versus 
the endosomal limiting membrane (peripheral, MEMB: grey), expressed as a percentage of 
total endosomal localization. Error bars are mean±s.d; n>20 endosomes. (e) Western blot 
analysis of sodium orthovanadate-induced phosphorylation in WT Cav1, ubiquitination-target 
lysine mutants, and non-phosphorylatable Y14F Cav1. (f) Cav1 inclusion in exosomes derived 
from fibroblasts (MEFs). Representative western blots of exosomal proteins floated on a 
continuous sucrose gradient (0.25-2M). Individual 1ml fractions were collected and after 
protein precipitation were loaded on electrophoresis gels and analyzed for Cav1 and the 
exosome marker Tsg101. (g) Western blot analysis of Cav1 in cell lysates and exosomes of 
COS-7 cells expressing HA-tagged Cav1 ubiquitination mutants. 
 
Figure 2. Cav1 regulates exosome biogenesis by modulating MVB cholesterol content 
Exosomes were isolated from supernatants of Cav1WT and Cav1KO fibroblast cultures. (a) 
Top. Western blots of Cav1, flotillin and the exosome marker Tsg101 in exosome extracts 




and Tsg101 in exosomes floated on a continuous sucrose gradient. (b) Quantification of 
exosome particles relative to producing cell number. (c) Nanosight distribution profiles of 
exosome preparations from Cav1WT and Cav1KO fibroblasts, showing greater morphological 
and size heterogeneity of Cav1WT-derived exosomes. The right panel shows quantification of 
the 2 exosome populations identified in Cav1WT and Cav1KO fibroblasts. Error bars are 
mean±s.e.m; n=10. (d) Representative transmission electron micrographs (TEM) of Cav1WT 
and Cav1KO exosomes (Scale bar 200 nm). Distribution profiles measured from TEMs of 
Cav1WT and Cav1KO fibroblasts-derived exosomes. (e) Filipin staining (in grey) and LBPA 
(in green) of Cav1WT, Cav1KO and U18666A-treated Cav1WT fibroblasts (Scale bar, 20 µm). 
The lower panel rows show zoomed views (Scale bar, 6 µm). Charts on the right show 
quantitative analysis of filipin mean fluorescence intensity in MVBs (upper) and total MVB area 
(lower). (f) Exosome production per cell (left) and Nanosight distribution profiles of exosome 
preparations (right) from Cav1WT fibroblasts without treatment (control) and treated with 
U18666A. (g) Western blots of sucrose density gradient fractions in the presence of triton X-
100 of exosomes produced by untreated Cav1WT and Cav1KO fibroblasts and U1866A-
treated Cav1WT fibroblasts. The chart shows the proportion of flotillin in detergent-resistant 
and non-resistant membranes. Error bars are mean±s.d; n=3. 
 
Figure 3. Cav1 specifies protein cargo into exosomes 
(a) Representation of hierarchical analysis of proteins equally expressed in the 2 parental cell 
populations (cell lysates, shaded in yellow) and differentially expressed in exosomes. Zq is 
the base 2 logarithm of protein ratios expressed in units of standard deviation, according to 
the WSPP model69,70. Blue indicates proteins upregulated in Cav1WT-MEF-derived 
exosomes, whereas red indicates proteins upregulated in Cav1-/--MEF-derived exosomes. 
The graphics on the right show STRING network analysis. Top. Interactions among identified 
proteins upregulated in Cav1WT-MEF-derived exosomes. Highlighted groups are related to 
extracellular matrix components (blue) and extracellular vesicle/exosome biogenesis and 
lysosome components (green). Bottom. Interactions among identified proteins upregulated in 
Cav1KO-MEF-derived exosomes. Highlighted groups are related to histones (red) and 
DNA/RNA conformation and binding (orange). (b) Clustered heatmap of extracellular proteins 
with significant changes in extracellular matrix protein abundance between exosomes 
produced by Cav1WT and Cav1KO fibroblasts (top) or in histone related proteins (bottom). (c) 
Heatmap comparing annexin isoform enrichment in exosomes produced by Cav1KO and 
Cav1WT fibroblasts; colour code as in (a). (d) Western blot analysis confirming the protein 
expression changes identified by quantitative proteomics in Cav1WT and Cav1KO fibroblast 





Figure 4. Exosome-mediated extracellular matrix deposition is caveolin-1 dependent 
(a) Z-stack projection of confocal microscopy images showing TnC (red) in matrix deposited 
by Cav1WT, Cav1KD and Cav1KO MEFs. F-actin is shown in green (Scale bar, 40 µm). 
Zoomed views reveal an absence of TnC matrix deposition and a corresponding increased 
intracellular accumulation (white arrow) in Cav1KD and Cav1KO MEFs (Scale bar, 10 µm). 
(b) TnC deposition of Cav1WT MEFs treated with U18666A determined by Z-stack projection 
confocal microscopy (Scale bar, 40 µm). (c) The chart shows extracellular TnC deposition in 
fibres produced by Cav1WT, Cav1KO and U18666A-treated Cav1WT MEFs, measured with 
in-house software (mean±s.d; n=8). (d) Western blot analysis of TnC downregulation in 
exosomes upon Cav1 depletion. TnC expression in exosomes secreted by Cav1-knockdown 
MEFs is compared with expression in exosomes derived from Cav1WT and Cav1KO 
counterparts. The chart shows TnC and Cav1 levels in each case (mean±s.e.m; n=6). (e) 
Representative immunofluorescence images showing the effect of 5-day exposure to the 
exosome inhibitors dimethylamyloride (dMA, 75 nM) and GW4869 (10M) on TnC matrix 
deposition (red) by Cav1WT MEFs (Scale bar, 20 µm). The chart to the right shows 
extracellular TnC deposition in fibres measured with in-house software (mean±s.e.m, n=12). 
(f) Representative Z-stack projection immunofluorescence confocal microscopy images 
showing the effect of 5-day exposure to dMA (75 nM) and GW4869 (10M) on FN matrix 
deposition (green) by Cav1WT MEFs (Scale bar, 50 µm). The chart to the right shows 
extracellular FN deposition in fibres measured with in-house software. Error bars are 
mean±s.e.m, n=5. (g) Representative Z-stack projection immunofluorescence confocal 
microscopy images showing the effect of siRNAs targeting Tsg101 and neutral 
sphingomyelinases 1 and 2 (nSMase1 and 2) on MEF TnC matrix deposition (red) (Scale bar, 
20 µm). The chart to the right shows extracellular TnC deposition in fibres measured as in c 
(mean±s.e.m; n=6).  
 
Figure 5. Exosomal incorporation of TnC occurs intracellularly via the ER-MVB route. 
(a) Western blot analysis of TnC and FN expression in lysates from TnCWT and TnCKO 
fibroblasts (left panels). Cell-derived matrices (CDMs) were generated from TnCWT and 
TnCKO cells as described in materials and methods, and TnCWT and TnCKO cells were 
plated on these CDMs as depicted. CDMs were labelled with TnC (in red) and the plated cells 
stained with F-actin (in grey) (Scale bar, 50 µm). (b) Western blot analysis of TnC and FN in 
total lysates (CDM+plated cells) and CDM-plated cells alone. Tubulin was used a loading 




scheme shows the assay protocol. The western blot shows analysis of TnC and FN binding to 
exosomes. (d) Subcellular fractionation analysis of intracellular TnC distribution in untreated 
Cav1WT fibroblasts, Cav1WT cells treated with GW4869, and Cav1KO cells. Western blot 
analysis was used to detect the MVB marker CD63 and the ER marker calreticulin. The boxed 
area denotes MVB-enriched fractions. The plots show the TnC present in MVB-enriched 
fractions in each condition (mean±s.d, n=3). (e) Colocalization analysis of TnC (red) and 
calreticulin (in green) in Cav1WT MEFs treated with GW4869 alone or in combination with the 
lysosomal inhitor chloroquine (Scale bar, 50 µm; zoomed views scale bar, 20 µm). 
Figure 6. TnC deposition mediated by exosomes promotes tumour cell invasiveness 
TnC deposition by exosomes was determined in 2D culture conditions. MDA-MB468 breast 
tumour cells were incubated with PKH67-labelled exosomes derived from Cav1WT or 
Cav1KO MEFs or with PBS (control). (a) Confocal microscopy analysis of exosome (green) 
uptake by MDA-MB468 cells and the deposition of exosome-delivered TnC (red) in areas 
surrounding the tumour cells. White arrowheads indicate TnC deposits. (Scale bar, 30 µm) (b) 
Phase-contrast and confocal microscopy analysis of morphological changes in MDA-MB468 
tumour cells 36 h after exposure to fibroblast-derived Cav1WT and Cav1KO exosomes. Cells 
were stained for the EMT marker E-cadherin; nuclei were stained with Hoescht. Zoomed 
images show E-Cadherin redistribution from cell-cell contact sites to intracellular 
compartments (Scale bar 10 µm). E-Cadherin was determined by western blot. (c) Z-stack 
confocal microscopy analysis of TnC deposition (red) within 3D MDA-MB468 spheroids 
generated in the presence of Cav1WT, Cav1KO or Cav1KD exosomes. Nuclei are stained 
with Hoechst (blue) (Scale bar, 150 µm). Zoomed images show a clear distribution of TnC 
deposits (Scale bar, 50 µm). White arrows indicate the presence of TnC fibres. The chart to 
the right shows extracellular TnC deposition in fibres into the spheroids (mean±s.e.m, n=3). 
(d) Phase contrast microscopy of MDA-MB468 spheroid migration (Scale bar, 175 µm). 
Spheroids were generated in the presence of the indicated exosomes, transferred to 96-well 
plates, and maintained in culture for 72 h. The graph shows quantitative analysis of spheroid 
migration (mean±s.e.m; n=11). (e) Invasiveness of MDA-MB468 spheroids generated in the 
presence of fibroblast-derived Cav1WT and Cav1KO exosomes. Invasiveness was assessed 
in matrigel by phase-contrast microscopy (Scale bar, 150 µm). (f) and collagen type I gel by 
immunofluorescence Z-stack confocal microscopy. Arrows indicate areas of cell invasion. 
Quantification of invasiveness of MDA-MB468 spheroids into collagen is shown (mean±s.e.m; 
n=24 spheroids per condition) (Scale bar, 100 µm). (g) Invasiveness of MDA-MB468 spheroids 
generated in the presence of fibroblast-derived TnCWT and TnCKO exosomes determined by 




MDA-MB468 spheroid invasiveness into collagen (mean±s.d; n=15 spheroids per condition; 
scale bar, 150 µm).  
Figure 7. Cav1-loaded fibroblast-derived exosomes deposit TnC in vivo in a tissue 
specific manner 
(a) Treatment protocol. (b) Fluorescence microscopy of liver sections from mice injected in the 
tail vein with Cav1WT or Cav1KO fibroblast-derived exosomes or with PBS (Scale bar, 60 µm; 
zoomed views, scale bar, 30 µm). Exosome foci are green. White arrows indicate regions of 
TnC deposition. All images are representative of nine random fields from two independent 
experiments. (c) Proposed role of Cav1 in exosome-mediated ECM deposition. (I) 
Endocytosed Cav1 enters the MVB compartment, where it promotes exosome heterogeneity 
in size and composition, favouring the entry of specific ECM components. (II) Cav1WT 
fibroblast-derived exosomes stimulate protrusive activity and motility of breast cancer cells by 
nucleating local extracellular matrix (TnC) deposition in areas surrounding the tumour cells. 
(III) Cav1WT fibroblast-derived exosomes also generate extracellular matrix-rich deposits at 
long distances from their source in vivo, generating sites of possible future metastasis. 
MATERIALS AND METHODS 
Antibodies and reagents 
Monoclonal anti-caveolin-1 (#3267) and anti-Alix (#2171) antibodies were from Cell Signaling 
Technology. Anti-LBPA was from Echelon (Z-SLBPA). Anti-CD63 (ab1318), anti-flotillin 
(ab13349), anti-periostin (ab14041), anti-Calreticulin (ab2907), anti-PTRF (ab48824) and anti-
TSG101 (ab83) were from Abcam. Anti-GM130 (610823), anti-py14-caveolin-1 (611339) and 
anti-Cadherin (610181) were from BD transduction. Anti-tubulin (T-9026), anti-Fibronectin 
(F3648) and anti-tenascin (Clone Mtn-12, T3413) were from Sigma. Anti-Tenascin was also 
from Millipore (AB19011). Anti-nSMAse1 (sc-377135) and anti-nSMAse2 (sc-166637) were 
from Santa Cruz. Alexa fluor 488, 546 and 647-conjugated phalloidin were from Life 
Technologies. GW4869 (567715) was from Calbiochem and dimethylamiloride (dMA) (A4562) 
was from Sigma. Matrigel (354230) was from BD and Collagen I from rat tail (354249) was 
from Corning. Filipin was from Sigma (F4767). 
Cell culture 
Mouse embryonic fibroblasts derived from Cav1WT and Cav1KO littermate mice used 
throughout this study were kindly provided by Dr. Michael P. Lisanti. TnCWT and TnCKO 
MEFs were provided by our collaborator Dr. Gertraud Orend. PTRFKO cells were provided by 




were from ATCC. MEFs and COS7 cells were cultured in Dulbecco´s modified Eagle medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml 
streptomycin at 37ºC in a humidified 5% CO2-95% air incubator. The breast cancer associated 
fibroblast line CCD-1069S and the breast tumour cell line MDA-MB468 were cultured in 
DMEM/F-12 supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. 
CCD-1069S fibroblasts stably expressing short hairpin RNA (shRNA) targeting Cav1 or a 
scramble siRNA were generated by lentiviral infection as reported in Goetz et al., 2011.  
siRNA silencing 
siRNA silencing was performed using 20 nM siRNA and Lipofectamine RNAiMAX Reagent 
(Thermo Fisher Scientific) according to the manufacturer´s protocol, and cells were cultured 
for 2-3 days. siRNAs targeting mouse Tsg101, nSMAse1 and nSMAse2 were SMARTpool 
ON-TARGET plus reagents from Dharmacon (Tsg101 Cat. L-049922-01-0005; nSMAse1 or 
Smpd2 Cat. L-044206-01-0005; nSmase2 or Smpd3 Cat. L-059400-01-0005). The control 
siRNA was ON-TARGET plus non-targeting pool (Dharmacon Cat. D-001810-10-05). Cav1 
was silenced with a siRNA from Dharmacon (seq. GAGCUUCCUGAUUGAGAUU) and an 
esiRNA from Sigma (EHU031251). 
Isolation and characterization of exosomes released by fibroblasts 
Exosomes were isolated from cultured fibroblasts grown in exosome-free culture medium. To 
remove detached cells, conditioned medium was collected and centrifuged at 300 g for 10 min 
at 4ºC. The supernatant was collected and centrifuged at 2000 g for 20 min at 4ºC. The 
supernatant was then centrifuged at 10000 g at 4ºC for 30 min to completely remove 
contaminating apoptotic bodies, microvesicles and cell debris. The clarified medium was then 
ultracentrifuged at 110,000 g at 4ºC for 70 min to pellet exosomes. The supernatant was 
carefully removed, and crude exosome-containing pellets were washed in ice-cold PBS. After 
a second round of ultracentrifugation, the resulting exosome pellets were resuspended in the 
desired volume of PBS. 
For further purification, exosomes were ultracentrifuged on a discontinuous sucrose gradient 
including sucrose concentrations of 0.25M, 0.5M, 0.8M, 1.16M, 1.3M and 2M in 20 mM 
HEPES, pH 7.4. Exosome samples were laid on the bottom of the gradient in the 2M sucrose 
fraction, followed by centrifugation at 200,000 g for 18 h. Eleven individual 1 ml gradient 
fractions were manually collected. Fractions were diluted in PBS and centrifuged at 110,000 
g for 1 h at 4ºC, and the resulting pellets were resuspended and analysed. Alternatively, an 
equal volume of cold acetone was added to each fraction and the proteins precipitated for 2 h 




to eliminate acetone traces. The protein precipitates were monitored by western blot for the 
expression of the exosomal markers Alix and Tsg101.  
In all experiments, the exosomes used corresponded to the total exosome pellets resulting 
from the serial centrifugation steps; usually 106 exosome particles were added per cell. 
Exosome uptake was performed in exosome-free medium. 
Exosome concentrations and size distributions were determined by Nanoparticle Tracking 
Analysis (Nanosight). 
Western blot analysis 
Western blot samples were prepared with conventional 5X Laemmli sample buffer brought to 
1X when mixed with the sample. The 5X Laemmli sample buffer is composed of 60 mM Tris-
HCl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, and 0.01% bromophenol blue.  
Cell or exosome proteins were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes. Blots were incubated for 2 h in PBS containing 5% skimmed milk and overnight 
with primary antibodies (typically diluted 1:1000). After incubation (2 h) with horseradish 
peroxidase-conjugated goat anti-rabbit or goat anti-mouse antibody, signal on washed blots 
was detected by enhanced chemiluminescence (GE Healthcare). Band intensities were 
quantified with Image J software. 
Intracellular lysate analysis 
To prepare lysates containing only proteins from the cell interior, plated cells were treated with 
trypsin to eliminate proteins in the extracellular space. Detached cells were washed with PBS 
and resuspended in loading buffer for western blot analysis. For total lysates comprising cell 
and ECM proteins, cells were scraped directly from the plate in loading buffer. 
PKH67 labelling of exosomes 
Purified exosomes were labelled with the green fluorescent dye PKH67 (Sigma MIDI67) 
according to the manufacturer´s protocol. After staining, unbound PKH67 was removed with 
columns from Thermo Fisher (4484449). 
Electron microscopy 
Exosomes were visualized by transmission electron microscopy (TEM) according to the 
method of Thery et al.71 . The exosome suspension was fixed in 2% paraformaldehyde and 
transferred to formvar/carbon coated electron microscopy grids. After 20 minutes, grids were 




were then transferred to 1% glutaraldehyde for 5 minutes and then washed with distilled water. 
Samples were contrasted in 2% uranyl acetate and examined by TEM. 
Spheroid formation assay 
After trypsinization, MDA-MB468 cells were resuspended in exosome-free DMEM, counted 
and adjusted to the desired concentration (usually 5X103 cells/ml). A 20 µL final volume was 
prepared with 5X methyl cellulose prepared in exosome-free medium, the MDA-MB468 cell 
suspension, and the desired number of exosomes (usually 1X106 particles). The mixture was 
carefully deposited in a drop on the inner surface of a 100 mm dish lid. The plate lid was placed 
on a plate containing 10 ml PBS to humidify the culture chamber. Under gravity, cells 
aggregated at the bottom of the hanging drop. After 24 hours, the resulting cell aggregates 
were lifted with a pipette. For 2D spheroid migration assays, the aggregates were seeded on 
a 96 well plate to monitor cell migration from the spheroid by phase-contrast time-lapse video 
microscopy. Alternatively, aggregates were seeded on collagen or matrigel gels as described 
below. In all assays, no additional exosomes were added to the medium apart from the 
exosomes used during spheroid generation. 
Collagen embedding 
High-density rat-tail type I collagen (Corning) was diluted to 2 mg/ml. This solution self-
polymerizes to form a gel after 20 to 30 min at 37 °C. Tumour cell spheroids were transferred 
to 25 µL unpolymerized collagen in the wells of a  slide angiogenesis plate (IBIDI). After 30 
min, 40 µL medium was added over the top of the gel. Medium was replaced every 48 h. 
Spheroids were imaged every 24 hours for the duration of the experiment. Spheroid diameter 
was measured from captured images with ImageJ. 
For matrigel embedding assays, spheroids were transferred to a 25 µL 1:1 mix of matrigel and 
medium. 
Wound closure assay 
For wound healing assay, confluent monolayers were scraped with a 0.1-2 μl pipette tip in the 
presence of mitomycin C, and wound closure was monitored by capturing images at 10-min 
intervals. 
Cell-derived matrix generation. 





Lysates and exosomes derived from WT and Cav1-/- MEFs were digested using the filter aided 
sample preparation (FASP) protocol72. Briefly, samples were dissolved in 50 mM Tris-HCl pH 
8.5, 4% SDS and 50 mM DTT, boiled for 10 min, and centrifuged. Protein concentration in the 
supernatant was measured with the Direct Detect® Spectrometer (Millipore). About 100 μg of 
protein were diluted in 8 M urea in 0.1 M Tris-HCl pH 8.5 (UA) and loaded onto 30 kDa 
centrifugal filter devices (FASP Protein Digestion Kit). The denaturation buffer was removed 
by washing three times with UA. Proteins were then alkylated by incubation in 50 mM 
iodoacetamide in UA for 20 min in the dark, and excess alkylation reagents were eliminated 
by washing three times with UA and three additional times with 50 mM ammonium 
bicarbonate. Proteins were digested overnight at 37ºC with modified trypsin (Promega) in 50 
mM ammonium bicarbonate at a 50:1 protein:trypsin (w/w) ratio. The resulting peptides were 
eluted by centrifugation with 50 mM ammonium bicarbonate (twice) and 0.5M sodium chloride. 
Trifluoroacetic acid (TFA) was added to a final concentration of 1% and the peptides were 
finally desalted onto C18 Oasis-HLB cartridges and dried-down for further analysis. 
Multiplexed isobaric labelling. For the quantitative analysis, tryptic peptides were dissolved 
in triethylammonium bicarbonate (TEAB) buffer, and the peptide concentration was 
determined by measuring amide bonds with the Direct Detect system. Equal amounts of each 
peptide sample were labelled using the 4-plex iTRAQ Reagents Multiplex Kit (Applied 
Biosystems). Briefly, each peptide solution was independently labelled at room temperature 
for 1 h with one iTRAQ reagent vial (mass tag 114, 115, 116 or 117) previously reconstituted 
with ethanol. After incubation at room temperature for 1 h, the reaction was stopped with 
diluted TFA and peptides were combined. Samples were concentrated in a Speed Vac, 
desalted onto C18 Oasis-HLB cartridges, and dried-down for mass spectrometry analysis.  
Mass spectrometry. Digested peptides were loaded into the LC-MS/MS system for on-line 
desalting onto C18 cartridges and analysed by LC-MS/MS using a C-18 reversed phase nano-
column (75 µm I.D. x 25 cm, 2 µm particle size, Acclaim PepMap RSLC, 100 C18; Thermo 
Fisher Scientific) in a continuous acetonitrile gradient consisting of 0-30% B for 240 min and 
50-90% B for 3 min (A= 0.5% formic acid; B=90% acetonitrile, 0.5% formic acid). A flow rate 
of 200 nl/min was used to elute peptides from the RP nano-column to an emitter nanospray 
needle for real time ionization and peptide fragmentation in an Orbitrap QExactive mass 
spectrometer (Thermo Fisher). During the chromatography run, we examined an enhanced 
FT-resolution spectrum (resolution=70,000) followed by the HCD MS/MS spectra from the 20 
most intense parent ions. Dynamic exclusion was set at 40 s. For increased proteome 
coverage, labelled samples were also fractioned by cation exchange chromatography (Oasis 
HLB-MCX columns); fractions were desalted and analysed using the same system and 




Protein identification and quantification. All spectra were analysed with Proteome 
Discoverer (version 1.4.0.29, Thermo Fisher Scientific) using SEQUEST-HT (Thermo Fisher 
Scientific). The Uniprot database, containing all mouse sequences (March 03, 2013), was 
searched with the following parameters: trypsin digestion with 2 maximum missed cleavage 
sites; precursor and fragment mass tolerances of 2 Da and 0.03 Da, respectively; methionine 
oxidation as a dynamic modification; and carbamidomethyl cysteine and N-terminal and Lys 
iTRAQ modifications as fixed modifications. Peptides were identified using the probability ratio 
method73, and false discovery rate (FDR) was calculated using inverted databases and the 
refined method 70 with an additional filtering for a precursor mass tolerance of 15 ppm74. 
Identified peptides had a FDR equal to or lower than 1% FDR. 
Proteins were quantified from reporter ion intensities and quantitative data analysed with 
QuiXoT, based on the WSPP statistical model 69,70 . In this model, protein log2-ratios are 
expressed as standardized variables, i.e. in units of standard deviation according to their 
estimated variances (Zq values).  
Liquid chromatography/mass spectroscopy analysis of exosome 
glycerophospholipids 
Exosome samples from WT and KO mice corresponding to 2.5 mg protein were used. Before 
lipid extraction, the following internal standards were added: 200 pmol each of 1,2-
dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-dilauroyl-sn-glycero-3-
phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoinositol, 1,2-dimiristoyl-sn-
glycero-3-phosphoserine, 1,2-dimiristoyl-sn-glycero-3-phosphate, and 1-heptadecanoyl-2-
arachidonoyl-3-phosphoglycerol, according to the method of Bligh and Dyer75. After 
evaporation of organic solvent under vacuum, the lipids were redissolved in 50 l solvent 
mixture (75% A, 25% B) and 40 µL was injected into an Agilent 1260 Infinity high-performance 
liquid chromatograph equipped with an Agilent G1311C quaternary pump and an Agilent 
G1329B Autosampler. The column was a FORTIS HILIC (150 x 3 mm, 3 µm particle size) 
(Fortis Technologies) protected with a Supelguard LC-Si (20 mm x 2.1mm) guard cartridge 
(Sigma-Aldrich). Glycerophospholipids and sphingomyelin were separated according to the 
procedure described by Axelsen et al.76, with minor modifications. Briefly, the mobile phase 
consisted of a gradient of solvent A (hexanes:isopropanol, 30:40, by volume) and solvent B 
(hexanes:isopropanol:20 mM AcONH4 in water, 30:40:7 by volume). The gradient started at 
75% A from 0 to 5 min, then decreased from 75% A to 40% A at 15min, from 40% A to 5% A 
at 20 min, holding at 5% until 40 min, and increasing to 75% at 41min. The column was then 
re-equilibrated by holding at 75% A for an additional 14 min before the next sample injection. 




electrospray interface of an API2000 triple quadrupole mass spectrometer (Applied 
Biosystems). The source parameters were set as follows: ion spray voltage, -4500 V; curtain 
gas, 20 psi; nebulizer gas, 35 psi; desolvation gas, 65 psi; temperature, 400˚C. Phospholipid 
species were analysed in Q1 with negative ionization. Compound parameters were fixed for 
all analysed species: declustering potential, -65 V; entrance potential, -10 V; focusing 
potential, -300 V; and collision cell exit potential, -10 V. Phospholipid species were detected 
as [M-H]- ions except for phosphatidylcholine and sphingomyelin species, which were detected 
as [M+OAc-]- adducts. For quantification, chromatographic peaks of each species were 
integrated and compared with the peak area of the internal standard corresponding to each 
phospholipid class. Since bis(monoacylglycerol)phosphate and sphingomyelin internal 
standards were unavailable at the time of analysis, these species were quantified using 1-
heptadecanoyl-2-arachidonoyl-3-phosphoglycerol and 1,2-dipentadecanoyl-sn-glycero-3-
phosphocholine standards, respectively. 
Subcellular fractionation  
Intracellular compartments were separated by sucrose density gradient centrifugation. Cells 
were washed three times in 10 mM Tris-HCl pH 7.5, 0.5 mM MgCl2 and then scraped and 
resuspended in 50 mM Tris-HCl pH 7.5, 0.25M sucrose. Cells were homogenized with 30 
strokes using a Dounce homogenizer. The homonogenates were then centrifuged at 3000g 
for 15 min at 4ºC. The supernatant was placed over a continuous sucrose gradient (2M at the 
bottom-0.25M at the top) and samples were separated at 100,000g for 18 hours in a SW40 
rotor (Beckman) at 4ºC. After centrifugation, 1 ml fractions were collected from the tube, 
yielding a total of 12 fractions. Cold acetone (1 ml) was added to each tube and the 
homogeneous mixture was allowed to precipitate at -20ºC for 2 h. The samples were 
centrifuged at 16,000g at 4ºC and the protein pellets were allowed to dry for 2 h. The protein 
precipitates were then analysed by SDS-PAGE for proteins, including the ER marker 
calreticulin and the MVB marker CD63. 
Preparation of detergent-resistant membrane fractions 
 
DRMs from exosomes derived from Cav1WT and Cav1KO MEFs were purified as described 
in Navarro-Lerida et al. JCS (2002) with the Triton X-100 concentration reduced from 1% to 
0.5%. 
Transwell migration assay 
The transwell migration assay was performed with Boyden chambers containing 8 µm pore-




exosomes was placed in the wells of a 24-well plate. The transwell inserts were placed in the 
wells and 5x104 MDA-MB468 cells in 200 l serum-free medium were added to the upper 
chamber. After incubation for 24 h, cells on the lower membrane surface were fixed and 
stained with crystal violet and counted under a microscope. 
Animal model 
All animal procedures conformed to EU Directive 86/609/EEC and Recommendation 
2007/526/EC regarding the protection of animals used for experimental and other scientific 
purposes, enforced in Spanish law under Real Decreto 1201/2005. Cav1WT and Cav1-/- 
exosomes were labelled with PKH67 and intravenously injected every day for one week into 
the tail vein of TnC-/- mice77 bred into the FVB background. After 4 days, lungs and livers were 
collected and embedded sections were analysed by immunohistochemistry with anti-TnC 
antibody (Sigma). 
Immunofluorescence microscopy  
Cells grown on glass coverslips were washed twice with PBS and fixed for 15 min at room 
temperature in 4% paraformaldehyde in PBS. Fixed cells were washed extensively with PBS 
and permeabilized for 5 min in PBS containing 0.1% Triton X100 and 2% BSA to reduce non-
specific binding. Cells were incubate for 1 h at room temperature in PBS containing 0.2% BSA 
with primary antibodies (typically diluted 1:200). Subsequent washes and incubations with 
Alexa fluor-647 or 546 phalloidin or fluorescent secondary antibodies were carried out in PBS 
for 1 h at room temperature. Coverslips were mounted in Permafluor aqueous mounting 
medium and examined with a Leica SPE, SP5 or SP8 confocal microscope. 
Filipin staining and quantification 
Cells were grown on glass coverslips. After fixing for 10 min at 37ºC with 4% 
paraformaldehyde in phosphate‐buffered saline (PBS), cells were permeabilized with 0.2% 
BSA and 0.1% saponin in PBS (blocking solution) for 30 minutes. Samples were then 
incubated with primary antibody (LBPA) and fluorescently labeled-conjugated secondary 
antibodies for 1h each, interspersed with three washes in blocking solution. After an additional 
wash in PBS, cells were incubated for 1h with filipin (50µg/ml in PBS). After three washes in 
PBS, slides were mounted in Fluoromount. Fiji software was used to quantify filipin 
fluorescence intensity (http://fiji.sc/). Cells were segmented based on LBPA staining. Filipin 




Quantitative real-time PCR 
Frozen tissues or cell lines were analysed for specific gene expression using SybrGreen PCR 
Reagents (Applied Biosystems) and specific primers: mouse Tsg101 sense 5’-
TCTAACCGTCCGTCAAACTGT-3’, antisense 5’-TTGTACCAGTGAGGTTCACCA-3’; mouse 
nSMase 2 sense 5’-ACACGACCCCCTTTCCTAATA-3’, antisense 5’-
GGCGCTTCTCATAGGTGGTG-3’; mouse nSMase 1 sense 5’-
TGGGACATCCCCTACCTGAG-3’, antisense 5’-TAGGTGAGCGATAGCCTTTGC-3’. Total 
RNA was extracted from tissues or cells using the RNeasy kit (Qiagen) and reverse-
transcribed. Quantitative real-time PCR was performed with a 7500Fast Real Time PCR 
System. Relative expression was normalized to GADPH and HPRT. 
Immunohistochemical staining 
Harvested tissues were fixed in 4% paraformaldehyde, processed through graded sucrose, 
embedded in OCT medium (Tissue-Tek) and stored at -80ºC. Frozen sections (20 µm) were 
dried for 10 minutes at room temperature and blocked for 1h in PBS containing 4% chicken 
serum and 0.3% TritonX-100. Sections were stained with anti-TnC antibody diluted 1:200 in 
blocking solution overnight at 4ºC. Samples were washed extensively in PBS, 0.15% TritonX-
100 for at least for 3 h. Samples were then incubated overnight with anti-rabbit Alexa fluor-
647 secondary antibody (1:200), Alexa-fluor 546-phalloidin (1:500) and Hoescht 33342 in 
blocking solution. After extensive washing, sections were mounted in Permafluor mounting 
medium. Confocal Z-stack images were captured and TnC deposits were quantified. 
Extracellular TnC and FN fiber quantification 
The procedure for image processing and quantification of “fibreness” was developed as a 
macro in Fiji (ImageJ 1.50e x64). Fibreness measures the amount of fibre-like structures in an 
image, providing a readout that takes into account both the density of fibres and their length, 
independently of orientation. Noise reduction first stabilizes the image background. The 
structural information from the eigen values of the Hessian matrix is then used to apply a 
Frangi vesselness filter74 to enhance very thin, almost unidimensional tubular structures (filter 
scale: σ=0.179 µm, close to pixel size). The output is a fibre-enhanced image where each 
pixel contains a fibreness score. M0 readout was computed as the mean fibreness score in 
the whole image. The processing pipeline and extracted M0 measures are illustrated in 






Error bars depict SEM. Statistical significance was determined with GraphPad Prism by 
unpaired Student's t-test or Mann-Whitney test, as indicated; * p<0.05, ** p<0.01, *** p<0.001. 
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